Cargando…

Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells

Pancreatic ductal adenocarcinoma (PDAC) progression and chemotherapy insensitivity have been associated with aberrant PI3K/mTOR/MEK signalling. However, cell death responses activated by inhibitors of these pathways can differ – contextually varying with tumour genetic background. Here, we demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmi, Rajpal S., Maginn, Elaina N., Gabra, Hani, Stronach, Euan A., Wasan, Harpreet S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343713/ https://www.ncbi.nlm.nih.gov/pubmed/30261145 http://dx.doi.org/10.1080/15384047.2018.1504718

Ejemplares similares

Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy
por: Dungl, Daniela A., et al.
Publicado: (2015)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
por: Tiwary, R, et al.
Publicado: (2011)

A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration
por: Hagenbuchner, Judith, et al.
Publicado: (2013)

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
por: Meng, Jieru, et al.
Publicado: (2010)

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022)

Trichonomas vaginalis Metalloproteinase Induces Apoptosis of SiHa Cells through Disrupting the Mcl-1/Bim and Bcl-xL/Bim Complexes
por: Quan, Juan-Hua, et al.
Publicado: (2014)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
por: Heavey, Susan, et al.
Publicado: (2016)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest
por: Haschka, Manuel D., et al.
Publicado: (2015)

Dynein light chain 1 induces assembly of large Bim complexes on mitochondria that stabilize Mcl-1 and regulate apoptosis
por: Singh, Prafull Kumar, et al.
Publicado: (2017)

Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen-independent prostate cancer cells
por: Choi, Eun-Sun, et al.
Publicado: (2013)

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
por: Rittler, Dominika, et al.
Publicado: (2020)

Roscovitine-induced Apoptosis in Neutrophils and Neutrophil Progenitors Is Regulated by the Bcl-2-Family Members Bim, Puma, Noxa and Mcl-1
por: Gautam, Sanjivan, et al.
Publicado: (2013)

Cyclic Marinopyrrole Derivatives as Disruptors of Mcl-1 and Bcl-x(L) Binding to Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide
por: Hadji, Abbas, et al.
Publicado: (2019)

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
por: Ho, Alan L., et al.
Publicado: (2012)

Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts
por: ANDERSEN, NICHOLAS J., et al.
Publicado: (2015)

Evodiamine Induces Apoptosis and Enhances TRAIL-Induced Apoptosis in Human Bladder Cancer Cells through mTOR/S6K1-Mediated Downregulation of Mcl-1
por: Zhang, Tao, et al.
Publicado: (2014)

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
por: Tran, Khanh B., et al.
Publicado: (2021)

Exposure to the Viral By-Product dsRNA or Coxsackievirus B5 Triggers Pancreatic Beta Cell Apoptosis via a Bim / Mcl-1 Imbalance
por: Colli, Maikel L., et al.
Publicado: (2011)

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
por: Chappell, William H., et al.
Publicado: (2011)

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response
por: McCubrey, James A., et al.
Publicado: (2012)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer
por: Butler, Dominika E., et al.
Publicado: (2017)

Correction: Roscovitine-induced Apoptosis in Neutrophils and Neutrophil Progenitors Is Regulated by the Bcl-2-Family Members Bim, Puma, Noxa and Mcl-1
por: Gautam, Sanjivan, et al.
Publicado: (2014)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway
por: Zheng, Xiangjin, et al.
Publicado: (2021)

MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma
por: Lee, J. Scott, et al.
Publicado: (2015)

BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
por: Sharma, A, et al.
Publicado: (2013)

Bim plays apoptosis offense
por: Powell, Kendall
Publicado: (2007)

mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma
por: Bailey, Sean T., et al.
Publicado: (2014)

Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma
por: Chadwick, Michelle L., et al.
Publicado: (2018)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
por: Alcon, Clara, et al.
Publicado: (2022)

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
por: Steelman, Linda S., et al.
Publicado: (2011)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Marinopyrrole Derivatives with Sulfide Spacers as Selective Disruptors of Mcl-1 Binding to Pro-Apoptotic Protein Bim
por: Cheng, Chunwei, et al.
Publicado: (2014)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
por: Milella, Michele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2t9jeh45999m51hn71amof5gc7